Genmab
| Company type | Public |
|---|---|
| Nasdaq Copenhagen: GMAB Nasdaq: GMAB (ADR) OMX Copenhagen 25 component | |
| Industry | Biotechnology |
| Founded | 1999 |
| Founder | Florian Schönharting and Lisa Drakeman |
| Headquarters | Copenhagen, Denmark |
Number of locations | 4 (2023) |
Key people |
|
| Products | DARZALEX/ DARZALEX FASPRO EPKINLY/TEPKINLY Kesimpta RYBREVANT TALVEY TECVAYLI TEPEZZA Tivdak |
| Revenue | DKK 16.474 billion (2023) |
| DKK 5.321 billion (2023) | |
| DKK 4.352 billion (2023) | |
Number of employees | 2,204 (2023) |
| Website | Genmab.com |
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US.